Table 1 Clinical characteristics of patients
|  | Population (N = 922) |
|---|---|
Age at diagnosis (years), median (IQR) | 52 (47, 59) |
PNI, median (IQR) | 45.9 (40.8, 49.9) |
SII, median (IQR) | 768.3 (486.2, 1260.1) |
CA125 (U/mL), median (IQR) | 584.2 (168.4, 1398.0) |
BMI (kg/m2), median (IQR) | 22.0 (20.3, 24.1) |
Histology | |
 High-grade serous carcinoma | 597 (64.8) |
 Low-grade serous carcinoma | 28 (3.0) |
 Endometrioid carcinoma | 73 (7.9) |
 Mucinous carcinoma | 81 (8.8) |
 Ovarian clear cell carcinoma | 80 (8.7) |
 Others | 63 (6.8) |
FIGO stage | |
 I | 191 (20.7) |
 II | 132 (14.3) |
 III | 518 (56.2) |
 IV | 81 (8.8) |
FIGO stage | |
 I-IIA | 224 (24.3) |
 IIB-IV | 698 (75.7) |
Tumor laterality | |
 Unilateral | 405 (43.9) |
 Bilateral | 517 (56.1) |
Ascites | |
 No | 254 (27.5) |
 Yes | 668 (72.5) |
Hydrothorax | |
 No | 807 (87.5) |
 Yes | 115 (12.5) |
Menopause | |
 No | 394 (42.7) |
 Yes | 528 (57.3) |
Comorbidities | |
 No | 775 (84.1) |
 Yes | 147 (15.9) |
Family history of cancer | |
 No | 775 (84.1) |
 Yes | 147 (15.9) |
Surgery methods | |
 Laparotomy | 721 (78.2) |
 Laparoscopy | 201 (21.8) |
Lymphadenectomy | |
 No | 236 (25.6) |
 Yes | 686 (74.4) |
Lymph node metastasis | |
 Negative | 443 (64.6) |
 Positive | 243 (35.4) |
Residual disease | |
 R0 | 478 (51.8) |
 R1 | 272 (29.5) |
 R2 | 172 (18.7) |
Postoperative chemotherapy | |
 No | 82 (8.9) |
 Yes | 840 (91.1) |
Chemotherapy cycle | |
 < 6 | 394 (42.7) |
 ≥ 6 | 528 (57.3) |
PARP inhibitors | |
 No | 912 (98.9) |
 Yes | 10 (1.1) |
Bevacizumab | |
 No | 918 (99.6) |
 Yes | 4 (0.4) |